Wecker: Brody’s Human Pharmacology, 5th Edition
Chapter 01: Pharmacodynamics: Receptors and Concentration-Response Relationships
Test Bank
Multiple Choice
1. The majority of medications available today act on which superfamily of cellular
membrane receptor?
A. Ligand-gated ion channel
B. G-protein-coupled receptor
C. Receptor tyrosine kinase
D. Nuclear hormone receptor
E. Cytokine receptor
ANS: B. The majority of drugs available act on G-protein-coupled receptors.
2. Nalbuphine is an effective pain reliever because of its activity at mu-opioid receptors.
However, if given to a patient who has recently received morphine (which also affects
mu-opioid receptors) for postoperative pain, nalbuphine can worsen his or her pain. Thus
nalbuphine is said to have what kind of activity at mu-opioid receptors?
A. Full agonist
B. Partial agonist
C. Competitive antagonist
D. Non-competitive antagonist
E. Allosteric modifier
ANS: B. Nalbuphine is a partial agonist at opioid receptors.
,Wecker: Brody’s Human Pharmacology, 5th Edition B. Liver
C. Brain
Chapter 02: Pharmacokinetics: Absorption, Distribution, Metabolism, and Elimination D. Heart
E. Lungs
Test Bank
ANS: C. The brain contains tight intercellular junctions, forming the “blood-brain
Multiple Choice barrier.”
1. Which of the following features of a drug would enhance its uptake in the GI tract? 5. Drugs commonly undergo all of the following types of metabolism in the liver
EXCEPT FOR:
A. Polar
B. Water soluble A. Polymerization
C. Ionized B. Conjugation
D. Low molecular weight C. Oxidation
E. Low concentration gradient D. Reduction
E. Hydrolysis
ANS: D. Of the options given, only a low molecular weight will increase uptake of a
drug by the GI tract. ANS: A. Polymerization is not a common process by which drugs are hepatically
metabolized.
2. Which organ contains predominantly tight intercellular junctions, thereby restricting
its uptake of drugs?
A. Kidney
B. Liver
C. Brain
D. Heart
E. Lungs
ANS: C. The brain contains tight intercellular junctions, forming the “blood-brain
barrier.”
3. Drugs commonly undergo all of the following types of metabolism in the liver
EXCEPT FOR:
A. Polymerization
B. Conjugation
C. Oxidation
D. Reduction
E. Hydrolysis
ANS: A. Polymerization is not a common process by which drugs are hepatically
metabolized.
4. Which organ contains predominantly tight intercellular junctions, thereby restricting
its uptake of drugs?
A. Kidney
,Wecker: Brody’s Human Pharmacology, 5th Edition Wecker: Brody’s Human Pharmacology, 5th Edition
Chapter 03: Clinical Pharmacokinetics and Issues in Therapeutics Chapter 04: Drug Development, Regulation, and Prescription Writing
Test Bank Test Bank
Multiple Choice Multiple Choice
1. Ketamine has a half-life of 2 ½ hours. If used as a continuous infusion at a dosage of 1. The following characterizes Phase 3 trials of drug development:
12.5 mg/hr for postoperative pain relief, how long will it take to achieve a practical
steady-state concentration? A. Conducted on several thousand patients with specific diseases to determine overall
risk-benefit relationships
A. 5 hours B. Conducted on a small number of normal volunteers to determine safe dosage range
B. 7 ½ hours and pharmacokinetic parameters
C. 10 hours C. Conducted on animals to determine what potential toxicities exist and at what serum
D. 12 ½ hours levels those toxicities are manifest
E. 15 hours D. Surveillance of a drug after release on the market to determine whether any
previously undetected side effects develop after extended use of the drug on large
ANS: D. The practical steady-state concentration is considered to occur after 5 half-lives. populations
5 times 2 ½ is 12 ½. E. Conducted on several hundred patients with specific diseases to determine short-term
safety and effectiveness of the drug
2. Which of the following is most likely increased in the average 70-year-old man
compared with the average 30-year-old man? ANS: A.
A. Body water percentage 2. In the United States, a “rare disease” is defined as one affecting fewer than what
B. Total lean body mass number of people?
C. Glomerular filtration rate
D. Carotid body baroceptor reflex A. 25,000
E. Plasma α-1 acid glycoprotein B. 50,000
C. 100,000
ANS: E. Of the options given, only α-1 acid glycoprotein plasma levels are increased in D. 200,000
the elderly. E. 400,000
3. For a 40-year-old, 75-kg man, drug X has a volume of distribution of 40 L and a ANS: D.
clearance of 25 ml/min. Calculate the predicted loading dose of drug X to achieve a
plasma concentration of 2 μg/ml. 3. Which of the following pairs of Latin abbreviations and English meanings is correct?
A. 20 μg A. QID = daily
B. 80 μg B. AC = after meals
C. 20 mg C. PO = by mouth
D. 50 mg D. BID = every 2 days
E. 80 mg E. = with
ANS: E. The loading dose is obtained by multiplying the goal plasma drug concentration ANS: C.
by the volume of distribution.
, Wecker: Brody’s Human Pharmacology, 5th Edition Wecker: Brody’s Human Pharmacology, 5th Edition
Chapter 05: Gene Therapy and Emerging Molecular Therapies Chapter 06: Antibodies and Biological Products
Test Bank Test Bank
Multiple Choice Multiple Choice
1. Which of the following is NOT a potential advantage of gene therapy over traditional 1. Which of the following medications typically enhances immunologic activity?
pharmacologic therapy?
A. Glatiramer
A. Gene therapy can replace a mutant gene that results in disease, thereby striking B. Methotrexate
the root of the condition. C. Cyclosporine
B. Gene therapy can result in continuous production of a therapeutic protein with D. Tacrolimus
a short t1/2 that would otherwise require frequent dosing. E. Sargramostim
C. Gene therapy in Phase 4 studies has been proven safer and more efficacious
than analogous drug treatments. ANS: E. Also known as “granulocyte-macrophage colony-stimulating factor” (GM-CSF),
D. Gene therapy can be targeted to a specific site or cell type to avoid potentially sargramostim enhances immunologic activity in patients suffering from deficiencies of
toxic systemic therapy. these types of leukocyte.
E. Gene therapy can improve patient compliance dramatically, since it does not
rely on daily adherence to a treatment. 2. Over the first 24 hours of glucocorticoid therapy, which group of leukocytes increases
in number?
ANS: C.
A. Neutrophils
2. Choose the true statement regarding gene transfer mechanisms. B. Eosinophils
C. Macrophages
A. Plasmid DNA transfer has the advantage of being highly efficient. D. Basophils
B. Retrovirus transfer is optimal when the target cell is undergoing division. E. Lymphocytes
C. The high rate of protein uptake makes liposomal transfer mechanisms less desirable.
D. Adenovirus transfer typically has effects lasting 3 years or longer. ANS: A. Glucocorticoids increase neutrophil count via enhanced release from the bone
E. Herpes simplex viruses are clinically used to transfer DNA to reproductive organs. marrow.
ANS: B. 3. This compound acts as an immunosuppressive drug via a DNA alkylating mechanism:
A. Mycophenolate mofetil
B. Tacrolimus
C. Dexamethasone
D. Infliximab
E. Cyclophosphamide
ANS: E.
Chapter 01: Pharmacodynamics: Receptors and Concentration-Response Relationships
Test Bank
Multiple Choice
1. The majority of medications available today act on which superfamily of cellular
membrane receptor?
A. Ligand-gated ion channel
B. G-protein-coupled receptor
C. Receptor tyrosine kinase
D. Nuclear hormone receptor
E. Cytokine receptor
ANS: B. The majority of drugs available act on G-protein-coupled receptors.
2. Nalbuphine is an effective pain reliever because of its activity at mu-opioid receptors.
However, if given to a patient who has recently received morphine (which also affects
mu-opioid receptors) for postoperative pain, nalbuphine can worsen his or her pain. Thus
nalbuphine is said to have what kind of activity at mu-opioid receptors?
A. Full agonist
B. Partial agonist
C. Competitive antagonist
D. Non-competitive antagonist
E. Allosteric modifier
ANS: B. Nalbuphine is a partial agonist at opioid receptors.
,Wecker: Brody’s Human Pharmacology, 5th Edition B. Liver
C. Brain
Chapter 02: Pharmacokinetics: Absorption, Distribution, Metabolism, and Elimination D. Heart
E. Lungs
Test Bank
ANS: C. The brain contains tight intercellular junctions, forming the “blood-brain
Multiple Choice barrier.”
1. Which of the following features of a drug would enhance its uptake in the GI tract? 5. Drugs commonly undergo all of the following types of metabolism in the liver
EXCEPT FOR:
A. Polar
B. Water soluble A. Polymerization
C. Ionized B. Conjugation
D. Low molecular weight C. Oxidation
E. Low concentration gradient D. Reduction
E. Hydrolysis
ANS: D. Of the options given, only a low molecular weight will increase uptake of a
drug by the GI tract. ANS: A. Polymerization is not a common process by which drugs are hepatically
metabolized.
2. Which organ contains predominantly tight intercellular junctions, thereby restricting
its uptake of drugs?
A. Kidney
B. Liver
C. Brain
D. Heart
E. Lungs
ANS: C. The brain contains tight intercellular junctions, forming the “blood-brain
barrier.”
3. Drugs commonly undergo all of the following types of metabolism in the liver
EXCEPT FOR:
A. Polymerization
B. Conjugation
C. Oxidation
D. Reduction
E. Hydrolysis
ANS: A. Polymerization is not a common process by which drugs are hepatically
metabolized.
4. Which organ contains predominantly tight intercellular junctions, thereby restricting
its uptake of drugs?
A. Kidney
,Wecker: Brody’s Human Pharmacology, 5th Edition Wecker: Brody’s Human Pharmacology, 5th Edition
Chapter 03: Clinical Pharmacokinetics and Issues in Therapeutics Chapter 04: Drug Development, Regulation, and Prescription Writing
Test Bank Test Bank
Multiple Choice Multiple Choice
1. Ketamine has a half-life of 2 ½ hours. If used as a continuous infusion at a dosage of 1. The following characterizes Phase 3 trials of drug development:
12.5 mg/hr for postoperative pain relief, how long will it take to achieve a practical
steady-state concentration? A. Conducted on several thousand patients with specific diseases to determine overall
risk-benefit relationships
A. 5 hours B. Conducted on a small number of normal volunteers to determine safe dosage range
B. 7 ½ hours and pharmacokinetic parameters
C. 10 hours C. Conducted on animals to determine what potential toxicities exist and at what serum
D. 12 ½ hours levels those toxicities are manifest
E. 15 hours D. Surveillance of a drug after release on the market to determine whether any
previously undetected side effects develop after extended use of the drug on large
ANS: D. The practical steady-state concentration is considered to occur after 5 half-lives. populations
5 times 2 ½ is 12 ½. E. Conducted on several hundred patients with specific diseases to determine short-term
safety and effectiveness of the drug
2. Which of the following is most likely increased in the average 70-year-old man
compared with the average 30-year-old man? ANS: A.
A. Body water percentage 2. In the United States, a “rare disease” is defined as one affecting fewer than what
B. Total lean body mass number of people?
C. Glomerular filtration rate
D. Carotid body baroceptor reflex A. 25,000
E. Plasma α-1 acid glycoprotein B. 50,000
C. 100,000
ANS: E. Of the options given, only α-1 acid glycoprotein plasma levels are increased in D. 200,000
the elderly. E. 400,000
3. For a 40-year-old, 75-kg man, drug X has a volume of distribution of 40 L and a ANS: D.
clearance of 25 ml/min. Calculate the predicted loading dose of drug X to achieve a
plasma concentration of 2 μg/ml. 3. Which of the following pairs of Latin abbreviations and English meanings is correct?
A. 20 μg A. QID = daily
B. 80 μg B. AC = after meals
C. 20 mg C. PO = by mouth
D. 50 mg D. BID = every 2 days
E. 80 mg E. = with
ANS: E. The loading dose is obtained by multiplying the goal plasma drug concentration ANS: C.
by the volume of distribution.
, Wecker: Brody’s Human Pharmacology, 5th Edition Wecker: Brody’s Human Pharmacology, 5th Edition
Chapter 05: Gene Therapy and Emerging Molecular Therapies Chapter 06: Antibodies and Biological Products
Test Bank Test Bank
Multiple Choice Multiple Choice
1. Which of the following is NOT a potential advantage of gene therapy over traditional 1. Which of the following medications typically enhances immunologic activity?
pharmacologic therapy?
A. Glatiramer
A. Gene therapy can replace a mutant gene that results in disease, thereby striking B. Methotrexate
the root of the condition. C. Cyclosporine
B. Gene therapy can result in continuous production of a therapeutic protein with D. Tacrolimus
a short t1/2 that would otherwise require frequent dosing. E. Sargramostim
C. Gene therapy in Phase 4 studies has been proven safer and more efficacious
than analogous drug treatments. ANS: E. Also known as “granulocyte-macrophage colony-stimulating factor” (GM-CSF),
D. Gene therapy can be targeted to a specific site or cell type to avoid potentially sargramostim enhances immunologic activity in patients suffering from deficiencies of
toxic systemic therapy. these types of leukocyte.
E. Gene therapy can improve patient compliance dramatically, since it does not
rely on daily adherence to a treatment. 2. Over the first 24 hours of glucocorticoid therapy, which group of leukocytes increases
in number?
ANS: C.
A. Neutrophils
2. Choose the true statement regarding gene transfer mechanisms. B. Eosinophils
C. Macrophages
A. Plasmid DNA transfer has the advantage of being highly efficient. D. Basophils
B. Retrovirus transfer is optimal when the target cell is undergoing division. E. Lymphocytes
C. The high rate of protein uptake makes liposomal transfer mechanisms less desirable.
D. Adenovirus transfer typically has effects lasting 3 years or longer. ANS: A. Glucocorticoids increase neutrophil count via enhanced release from the bone
E. Herpes simplex viruses are clinically used to transfer DNA to reproductive organs. marrow.
ANS: B. 3. This compound acts as an immunosuppressive drug via a DNA alkylating mechanism:
A. Mycophenolate mofetil
B. Tacrolimus
C. Dexamethasone
D. Infliximab
E. Cyclophosphamide
ANS: E.
